The first-in-class drug SCM-198 developed in this research was transferred to the enterprise for industrialization at RMB 150 million, and 2 clinical research approvals were obtained in China (Phase I clinical studies have been completed and Phase II studies have been initiated), and the US FDA is also approving the development Clinical research work is one of the few representatives of China's first-in-class drugs that will soon be approved for clinical research in the United States. In recent years, another first-in-class new drug with independent intellectual property rights has also been industrialized by 101 million yuan. The molecular pharmacological research method found that the unique role of HDAC4 in vascular inflammation was reviewed by top journal -- Cardiov. Res. as an era for vascular inflammation. Combined with the discovery of new drugs based on pharmacology over the years, our series of work was reviewed in September 2012 when the top magazine Science reported on the development of biomedicine in China. Professor Zhu was one of the most successful Chinese returned scientists (published on September 28, 2012, page no. 1692). Then, in 2017, C&EN, a news journal of the American Chemical Society reported on Professor Zhu’s experience in drug development and praised him as one of the pioneers of innovative drug research in China, which attracted great attention from the world (2017 April March 27-29). Our work created an effective exploration at Fudan University and Macau University of Science and Technology from traditional compound synthesis and screening to acquisition based on pharmacological research, institutional transformation or design of new compounds, and laid a good foundation for the development of new drug research in Macau.

Fig. 1 The first-in-class drug SCM-198 developed in this research was transferred to the enterprise for industrialization at RMB 150 million, and Phase I clinical studies have been completed and Phase II studies have been initiated.

Fig 2 The patents of first-in-class novel compound was tech-transferred by a Hong Kong Biotech company for an amount exceeding RMB 100 million.